Marta Altieri

Dr. Marta Altieri

Sapienza Univeristy of Rome
orcid

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 June 2004 in Neurology
Verified
Journal Article
Closed access
PDF file
Marta AltieriMarta Altieri
Marta Altieri
VPV. Di Piero
V. Di Piero
MPM. Pasquini
M. Pasquini
MGM. Gasparini
M. Gasparini
NVN. Vanacore
N. Vanacore
GLG. L. Lenzi
G. L. Lenzi
Objective: To assess patients who have had a stroke for the subsequent development of poststroke dementia (PSD) and to determine if the characteristics of delayed PSD (dPSD) vary in the long-term follow-up. Methods: Nondemented patients were followed from 6 months after stroke onset for 4 years. Dementia was diagnosed by International Classification of Diseases-10 criteria; dementia etiology was diagnosed by the National Institute of Neurological and Communication Disorders and Stroke/Alzheimer’s Disease and Related Disorders Association and National Institute of Neurologic Disorders and Stroke/Association Internationale pour la Recherche et l’Enseignement en Neurosciences criteria. Neuroimaging and neuropsychological tests were repeated annually. Results: During a 2-year period, 191 stroke patients were enrolled. By the end of the follow-up period, 41 (21.5%) patients had developed dementia. At the Cox regression analysis, dPSD was associated with cortical atrophy (hazard ratio [HR] = 3.4, 95% CI 1.5 to 7.9), age (HR = 3.3, 95% CI 1.4 to 7.8), and multiple ischemic lesions (HR = 2.5, 95% CI 1.2 to 4.8). The Kaplan-Meier analysis showed a significant difference between the incidence of dPSD subtypes (log-rank test; p = 0.002). Conclusions: During the 4-year follow-up, the incidence of dementia increased gradually, shifting from an Alzheimer disease-type picture in the first years to a vascular dementia type later in years 2 to 4.

19 December 2011 in European Journal of Neurology
Verified
Journal Article
Closed access
PDF file
Marta AltieriMarta Altieri
Marta Altieri
IMI. Maestrini
I. Maestrini
AMA. Mercurio
A. Mercurio
PTP. Troisi
P. Troisi
ESE. Sgarlata
E. Sgarlata
GLG. L. Lenzi
G. L. Lenzi

1 March 2009 in Cephalalgia
Verified
Journal Article
Closed access
PDF file
Marta AltieriMarta Altieri
Marta Altieri
RGR Di Giambattista
R Di Giambattista
LCL Di Clemente
L Di Clemente
DFD Fagiolo
D Fagiolo
ETE Tarolla
E Tarolla
VPV Di Piero
V Di Piero

20 August 2018 in The Journal of Headache and Pain
Verified
Journal Article
Open access
PDF file
AVAlessandro Viganò
Alessandro Viganò
MTMaria Claudia Torrieri
Maria Claudia Torrieri
MTMassimiliano Toscano
Massimiliano Toscano
FPFrancesca Puledda
Francesca Puledda
BPBarbara Petolicchio
Barbara Petolicchio
VPVittorio Di Piero
Vittorio Di Piero
Therapeutic management of Chronic Migraine (CM), often associated with Medication Overuse Headache (MOH), is chiefly empirical, as no biomarker predicting or correlating with clinical efficacy is available to address therapeutic choices. The present study searched for neurophysiological correlates of Greater Occipital Nerve Block (GON-B) effects in CM. We recruited 17 CM women, of whom 12 with MOH, and 19 healthy volunteers (HV). Patients had no preventive treatment since at least 3 months. After a 30-day baseline, they received a bilateral betamethasone-lidocaine GON-B of which the therapeutic effect was assessed 1 month later. Habituation of visual evoked potentials (VEP) and intensity dependence of auditory evoked potentials (IDAP) were recorded before and 1 week after the GON-B. At baseline, CM patients had a VEP habituation not different from HV, but a steeper IDAP value than HV (p = 0.01), suggestive of a lower serotonergic tone. GON-B significantly reduced the number of total headache days per month (− 34.9%; p = 0.003). Eight out 17CM patients reversed to episodic migraine and medication overuse resolved in 11 out of 12 patients. One week after the GON-B VEP habituation became lacking respect to baseline (p = 0.01) and to that of HV (p = 0.02) like in episodic migraine, while the IDAP slope significantly flattened (p < 0.0001). GON-B-induced reduction in headache days positively correlated with IDAP slope decrease (rho = 0.51, p = 0.03). GON-B may be effective in the treatment of CM, with or without MOH. The pre-treatment IDAP increase is compatible with a weak central serotonergic tone, which is strengthened after GON-B, suggesting that serotonergic mechanisms may play a role in CM and its reversion to episodic migraine. Since the degree of post-treatment IDAP decrease is correlated with clinical improvement, IDAP might be potentially useful as an early predictor of GON-B efficacy.

26 October 2011 in BMC Neurology
Verified
Journal Article
Open access
PDF file
SBStefano Bastianello
Stefano Bastianello
ARAlfredo Romani
Alfredo Romani
GVGisela Viselner
Gisela Viselner
ETEnrico Colli Tibaldi
Enrico Colli Tibaldi
EGElisabetta Giugni
Elisabetta Giugni
RBRoberto Bergamaschi
Roberto Bergamaschi
Chronic cerebrospinal venous insufficiency (CCSVI) has recently been reported to be associated with multiple sclerosis (MS). However, its actual prevalence, possible association with specific MS phenotypes, and potential pathophysiological role are debated.

13 January 2023 in Life
Verified
Journal Article
Open access
PDF file
Arianna Di StadioArianna Di Stadio
Arianna Di Stadio
Evanthia BernitsasEvanthia Bernitsas
Evanthia Bernitsas
Ignazio La MantiaIgnazio La Mantia
Ignazio La Mantia
Michael J. BrennerMichael J. Brenner
Michael J. Brenner
Massimo RalliMassimo Ralli
Massimo Ralli
Marta AltieriMarta Altieri
Marta Altieri
Chronic olfactory dysfunction after SARS-CoV-2 infection occurs in approximately 10% of patients with COVID-19-induced anosmia, and it is a growing public health concern. A regimen of olfactory training and anti-neuroinflammatory therapy with co-ultramicronized palmitoylethanolamide with luteolin (um-PEA-LUT) has shown promising results in clinical trials; however, approximately 15% of treated patients do not achieve full recovery of a normal olfactory threshold, and almost 5% have no recovery. Disease-modifying therapies (DMTs), which are used to treat autoimmune neuroinflammation in multiple sclerosis (MS), have not been studied for treating persistent inflammation in refractory post-COVID-19 smell disorder. This study evaluated COVID-19-related smell loss and MS-related smell loss, comparing the responses to different therapies. Forty patients with MS and 45 reporting post-COVID-19 olfactory disorders were included in the study. All patients underwent nasal endoscopy and were evaluated by using validated Sniffin’ Sticks testing. The patients with long COVID were treated for three months with um-PEA-LUT plus olfactory training. The patients with MS were treated with DMTs. Olfactory functions before and after treatment were analyzed in both groups. At the experimental endpoint, 13 patients in the COVID-19 group treated with um-PEA-LUT had residual olfactory impairment versus 10 patients in the MS group treated with DMTs. The severity of the persistent olfactory loss was lower in the MS group, and the patients with MS treated with IFN-beta and glatiramer acetate had the preservation of olfactory function. These data provide a rationale for considering prospective trials investigating the efficacy of DMTs for post-COVID-19 olfactory disorders that are refractory to um-PEA-LUT with olfactory training. This study is the first to consider the role of DMT in treating refractory post-viral olfactory loss in patients with long COVID.